Eton Pharmaceuticals, Inc. business relationships
Companies named in Eton Pharmaceuticals, Inc.’s 10-K filed 2026-03-19, and public companies whose annual reports name Eton Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 55% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Eton Pharmaceuticals, Inc.’s annual report 2
“During the twelve months ended December 31, 2025, the Company recognized $ 5,094 in inventory step-up expense associated with the inventory purchase from Ipsen S.A.” SEC filing
“In March 2025, the Company out-licensed the commercial rights to INCRELEX® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. ("Esteve").” SEC filing
Companies whose annual reports name Eton Pharmaceuticals, Inc. 1
“License and Supply Agreement with Eton Pharmaceuticals, Inc.” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms